Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has been confirmed by a tissue test (high-grade serous type is preferred).
• People whose cancer has come back or stopped responding to treatment after at least 2 previous rounds of systemic treatment, including at least one platinum-based chemotherapy (unless that type of chemotherapy was not suitable for them).
• People whose cancer can be measured on scans, using standard measurement guidelines called RECIST v1.1.
• People whose tumour shows high enough levels of at least two specific proteins — called MSLN, FRalpha (FOLR1), and MUC16 (CA 125) — confirmed through a tissue sample (either stored or freshly taken).
• People who are generally well enough to carry out daily activities with little to no limitation, based on a standard medical fitness scale (ECOG score of 0 or 1).
• People whose blood counts and organ function meet the required levels — including white blood cells, platelets, haemoglobin, liver enzymes, bilirubin, and kidney function (confirm specific numbers with the trial site).
• Women who could become pregnant must have a negative pregnancy test before joining and must agree to use effective contraception for 12 months after the treatment infusion, or as required under local gene therapy guidelines.
• People who are able to follow the study schedule and attend all required visits, and who are willing to give written consent to participate.

Who may not be able to join:

• People who have received a gene-modified cell therapy — such as CAR-T or CAR-NK therapy — within the past 6 months, or who have previously received any therapy targeting the same proteins as this trial.
• People who have active cancer spread to the brain or the lining around the brain that currently requires treatment.
• People with an uncontrolled infection, including active tuberculosis, or a serious viral infection that is not under control.
• People with HIV where the virus is not being adequately controlled, or people with active hepatitis B or hepatitis C with a detectable viral load (blood tests for these will be required at screening).
• People with serious heart conditions, such as a recent heart attack, an uncontrolled irregular heartbeat, or severe heart failure (confirm specific heart failure classification with trial site).
• People with an active autoimmune disease that has required immune-suppressing medication within the past 30 days (low-dose steroid replacement for a hormone deficiency may still be acceptable — confirm with trial site).
• People who are currently receiving other cancer treatments — such as chemotherapy, targeted therapy, or radiotherapy — unless enough time has passed since the last dose, as defined by the trial's washout period (confirm timing with trial site).
• People who have had major surgery within 4 weeks before the lymphodepletion stage of the trial (minor procedures may be acceptable — confirm with trial site).
• People who are pregnant or breastfeeding.
• People with any other condition that the trial doctor believes would make participation unsafe or affect the reliability of the trial results — for example, severe lung disease (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.